Solving the Puzzle
of Lung Cancer Complexity
with Artificial Intelligence

What is I3LUNG

I3LUNG is a European project funded under the framework of the H2020 call “Ensuring access to innovative, sustainable and high-quality health care”. Our consortium gathers 16 partners with different expertise located worldwide, with the common goal of providing better assistance and individualize treatment for patients affected by metastatic lung cancer.

For Patients

In the video below the project explained by Anne-Marie Baird, President of Lung Cancer Europe (LuCE) (one of the partners of the I3LUNG).

We are excited to start this project which is envisioned to both generate novel therapeutic guidelines for clinical practice in lung cancer and support the growth of digital diagnostic tools in the European industry. (I3LUNG Partners)

Find out the most relevant news on the latest advancements in lung cancer!

Economic Impact Assessment

The Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy (I3LUNG) consortium, funded by Horizon Europe, is […]

European Lung Cancer Congress, highlights of innovative treatments in the era of personalized medicine.

  On 29 of March -1 of April took place the ESMO – European Lung Cancer Congress in Copenhagen, Denmark, […]

Personalized Medicine and the Limitations of Molecular Biomarkers

Cancer is a complex disease caused by mutations in DNA. Over the years, significant progress has been made in understanding […]